Brief: Alzamend Neuro Receives FDA 'Study May Proceed' Notification For A Phase IIa Clinical Trial Of Al001, In Bipolar Disorder Patients

Alzamend Neuro

02/10/2023 14:35

Oct 2 (Reuters) - Alzamend Neuro Inc  ALZN.O :
    * ALZAMEND NEURO RECEIVES FDA “STUDY MAY PROCEED”
NOTIFICATION FOR
A PHASE IIA CLINICAL TRIAL OF AL001, A NEXT-GENERATION LITHIUM
THERAPEUTIC DRUG CANDIDATE, IN BIPOLAR DISORDER PATIENTS
    * ALZAMEND NEURO INC - SAFETY ASPECTS OF AL001 DEVELOPMENT
MAY
QUALIFY FOR A SECTION (505)(B)(2) NDA PATHWAY IN SUPPORT OF FDA
APPROVAL

Source text for Eikon:  ID:nBw4z4gBXa 
Further company coverage:  ALZN.O 

 ((Reuters.Briefs@thomsonreuters.com;))